Sensei Biotherapeutics (NASDAQ:FTH) Announces Earnings Results

Sensei Biotherapeutics (NASDAQ:FTH) posted its earnings results on Tuesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.13), Zacks reports.

Sensei Biotherapeutics Stock Performance

Shares of FTH traded up $0.70 during trading hours on Tuesday, reaching $19.93. 16,869 shares of the company’s stock traded hands, compared to its average volume of 251,708. Sensei Biotherapeutics has a 12 month low of $7.45 and a 12 month high of $42.14. The company has a market capitalization of $514.94 million, a PE ratio of -0.14 and a beta of -0.14. The firm’s 50 day simple moving average is $28.55.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Needham & Company LLC started coverage on Sensei Biotherapeutics in a report on Friday, August 21st. They set a “buy” rating and a $56.00 price objective on the stock. Citizens Jmp began coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective on the stock. Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. Finally, Lifesci Capital raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.